Finding biomarkers of resistance to targeted cancer therapies

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 109-114

  Bernards, René ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; RNA; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC APPROACH ROUTE; DNA MICROARRAY; DRUG COST; DRUG POTENCY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 35548992807     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70031-9     Document Type: Article

References (30)

1. Arteaga C., and Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell 5 6 (2004) 525-531
2. Weinstein I., and Joe A. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 8 (2006) 448-457
3. Druker B. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1 1 (2002) 31-36
4. Ross J., Schenkein D., Pietrusko R., et al. Targeted therapies for cancer 2004. Am J Clin Pathol 122 4 (2004) 598-609
5. Glas A., Floore A., Delahaye L., et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7 (2006) 278
6. van 't Veer L., Dai H., van de Vijver M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
7. Harris L., You F., Schnitt S., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13 4 (2007) 1198-1207
8. Potti A., Dressman H., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 11 (2006) 1294-1300
9. Staunton J., Slonim D., Coller H., et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98 19 (2001) 10787-10792
10. Schmitt C., Fridman J., Yang M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 3 (2002) 335-346
11. Kortlever R., Higgins P., and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8 8 (2006) 877-884
12. Dirac A., and Bernards R. Reversal of Senescence in Mouse Fibroblasts through Lentiviral Suppression of p53. J Biol Chem 278 14 (2003) 11731-11734
13. Bild A., Potti A., and Nevins J. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6 9 (2006) 735-741
14. Bild A., Yao G., Chang J., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 7074 (2006) 353-357
15. Jansen M., Foekens J., van Staveren I., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 4 (2005) 732-740
16. Cho H., Mason K., Ramyar K., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 6924 (2003) 756-760
17. Slamon D., Clark G., Wong S., Levin W., Ullrich A., and McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
18. Vogel C., Cobleigh M., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
19. Cobleigh M., Vogel C., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
20. Nagata Y., Lan K., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
21. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 5308 (1997) 1943-1947
22. Fujita T., Doihara H., Kawasaki K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94 2 (2006) 247-252
23. Saal L., Holm K., Maurer M., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65 7 (2005) 2554-2559
24. Azam M., Latek R., and Daley G. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 6 (2003) 831-843
25. Brummelkamp T., and Bernards R. New tools for functional mammalian cancer genetics. Nat Rev Cancer 3 10 (2003) 781-789
26. Vassilev L. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3 4 (2004) 419-421
27. Lane D., and Fischer P. Turning the key on p53. Nature 427 6977 (2004) 789-790
28. Vassilev L., Vu B., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 5659 (2004) 844-848
29. Berns K., Hijmans E., Mullenders J., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 6981 (2004) 431-437
30. Brummelkamp T., Fabius A., Mullenders J., et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2 4 (2006) 202-206